- Home
- TPST vs BOLD Comparison
TPST vs BOLD Comparison
Compare TPST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- BOLD
- Stock Information
- Founded
- TPST 2011
- BOLD 2018
- Country
- TPST United States
- BOLD United States
- Employees
- TPST N/A
- BOLD N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- TPST Health Care
- BOLD
- Exchange
- TPST Nasdaq
- BOLD Nasdaq
- Market Cap
- TPST 33.0M
- BOLD 24.4M
- IPO Year
- TPST N/A
- BOLD 2024
- Fundamental
- Price
- TPST $6.92
- BOLD $1.15
- Analyst Decision
- TPST Hold
- BOLD Buy
- Analyst Count
- TPST 3
- BOLD 3
- Target Price
- TPST $30.00
- BOLD $4.00
- AVG Volume (30 Days)
- TPST 86.6K
- BOLD 277.1K
- Earning Date
- TPST 08-07-2025
- BOLD 08-11-2025
- Dividend Yield
- TPST N/A
- BOLD N/A
- EPS Growth
- TPST N/A
- BOLD N/A
- EPS
- TPST N/A
- BOLD N/A
- Revenue
- TPST N/A
- BOLD N/A
- Revenue This Year
- TPST N/A
- BOLD N/A
- Revenue Next Year
- TPST N/A
- BOLD N/A
- P/E Ratio
- TPST N/A
- BOLD N/A
- Revenue Growth
- TPST N/A
- BOLD N/A
- 52 Week Low
- TPST $5.35
- BOLD $1.00
- 52 Week High
- TPST $30.03
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- TPST 46.64
- BOLD N/A
- Support Level
- TPST $7.06
- BOLD N/A
- Resistance Level
- TPST $7.64
- BOLD N/A
- Average True Range (ATR)
- TPST 0.26
- BOLD 0.00
- MACD
- TPST 0.00
- BOLD 0.00
- Stochastic Oscillator
- TPST 22.10
- BOLD 0.00
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.